Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials

INTRODUCTION: Temporary dose modifications, such as reductions or interruptions, may allow patients to better manage adverse events (AEs) associated with pirfenidone use and continue treatment for idiopathic pulmonary fibrosis (IPF). However, the impact of such dosing adjustments on efficacy and saf...

Full description

Saved in:
Bibliographic Details
Published in:BMJ Open Respir Res
Main Authors: Nathan, Steven D, Lancaster, Lisa H, Albera, Carlo, Glassberg, Marilyn K, Swigris, Jeffrey J, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Limb, Susan L, Petzinger, Ute, Noble, Paul W
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2018
Subjects:
Interstitial Lung Disease
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089326/
https://ncbi.nlm.nih.gov/pubmed/30116539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2018-000323
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items